copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Turning 18 Months into 18 Years | Mount Sinai - New York When Bill was first informed of his advanced disease (Gleason Total Score 9, Grade T-3A) in 1995, the recommendation to go on hormone therapy with Lupron In addition, Bill made dramatic lifestyle changes: healthy low-fat, high-fiber foods; meditation; and a gym membership
Active Surveillance | Mount Sinai - New York Active surveillance is most appropriate for you medically if: You aren’t experiencing any symptoms You have a slow-growing cancer (Gleason score of less than 6) Your cancer is small (cannot be seen on a digital rectal exam or ultrasound) The cancer is only in the prostate (localized) You have a low PSA level (less than 10 mg ml)
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer . . . Summary: This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance Eligibility: Inclusion Criteria: - Written informed consent and HIPAA authorization for release of personal health information NOTE: HIPAA authorization may be included in the informed consent or
Pathology Test Uses Artificial Intelligence to Predict Prostate Cancer . . . A pathology test that applies artificial intelligence (AI) to characterize tissue samples can accurately predict clinically significant prostate cancer disease progression following surgery, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published in Nature Prostate Cancer and Prostatic Diseases The Precise MD post-op test automates the Gleason score (a
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in . . . - With a Gleason score of ≤6, treated within the last 24 months, or untreated and under surveillance - With a Gleason score of 3+4 that has been treated >6 months prior to full study screening and considered to have a very low risk of recurrence, or
A Study of BION-1301 in Adults With IgA Nephropathy Participants with low-risk prostate cancer (i e , Gleason score < 7 and prostate specific antigen < 10 ng mL) are allowed - Pregnancy or breastfeeding or intent to become pregnant or to donate sperm during the study period and until 24 weeks after last dose